Journal of Neural Transmission

, Volume 67, Issue 3–4, pp 287–292

Iron, a new aid in the treatment of Parkinson patients

  • W. Birkmayer
  • J. G. D. Birkmayer
Article

Summary

One of the problems in treating Parkinson patients is the so called “off-effect” which occurs after long term treatment with L-DOPA. Off-effects are characterized by severe rigor and akinesia. Increasing dosages of L-DOPA and decarboxylase- or monoaminooxidase-inhibitors do not improve these symptoms. Intravenously applied iron-in form of a ferri-ferro-complex-exhibited a considerable benefit for all patients treated so far. They regained a remarkable mobility. Their disability score dropped from up to 90% down to 30%. The effect of iron is dosage-dependent and lasts 24 to 48 hours.

Key words

Parkinson disease akinesia iron phenylalanine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Birkmayer W, Hornykiewicz O (1961) Der L-Dioxyphenylalanin (L-DOPA)-Effekt bei der Parkinson-Akinesie. Wien Klin Wochenschr 73: 787Google Scholar
  2. Birkmayer W (1969) Experimentelle Ergebnisse über die Kombinations-behandlung des Parkinson-Syndroms mit L-DOPA und einem Decarbo-xylasehemmer. Wien Klin Wochenschr 81: 677Google Scholar
  3. Birkmayer W, Neumayer E (1972) Die moderne medikamentöse Behandlung des Parkinsonismus. Z Neurol 202: 257Google Scholar
  4. Birkmayer W, Riederer P, Youdim MBH, Linauer W (1975) The potentiation of the anti-akinetic effect after L-DOPA treatment by an inhibitor of MAO-B, Deprenyl. J Neural Transm 36: 303Google Scholar
  5. Birkmayer W, Riederer P (1985) Die Parkinson-Krankheit, 2. Aufl. Springer, Wien New YorkGoogle Scholar
  6. Carlsson A, Lindquist M, Magnusson T (1957) 3,4-Dihydroxyphenylalanine ad 5-hydroxytryptophan as reserpine antagonists. Nature 180: 1200Google Scholar
  7. Carlsson A, Lindquist M, Magnusson T, Waldeck B (1958) On the presence of 3-hydroxytyramine in brain. Science 137: 471Google Scholar
  8. Nagatsu T, Namaguchi T, Kato T, Sugimoto T, Matsuura S, Akino M, Nagatsu I, Iizuka R, Narabayashi H (1981) Biopterin in human brain and urine from controls and parkinsonian patients: application of a new radioimmuno assay. Clin Chim Acta 109: 305–311Google Scholar
  9. Riederer P, Sofic E, Rausch WD, Kruzik P, Youdim MBH (1985) Dopamin-forschung heute und morgen—L-DOPA in der Zukunft. In: Riederer P, Umek H (eds) L-Dopa-Substitution der Parkinson-Krankheit. Springer, Wien New York, pp 127–140Google Scholar

Copyright information

© Springer-Verlag 1986

Authors and Affiliations

  • W. Birkmayer
    • 1
  • J. G. D. Birkmayer
    • 2
  1. 1.Evangelic HospitalWienAustria
  2. 2.Department of Medical ChemistryUniversity of GrazAustria

Personalised recommendations